Eli Lilly’s late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results.

A cure for diabetes has been top of mind for many that live with the conditions under the term’s umbrella. But type 1 diabetes, in particular, is an irreversible lifelong autoimmune condition. But new ...

Learn why GLP-1 use isn’t included in how experts define type 2 diabetes remission despite the drugs’ ability to help manage blood sugar and reduce a person’s A1C.

A recent study revealed that nearly one in 10 people may show minimised response to GLP-1 receptor agonists, commonly used ...

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

Obesity therapeutics now represent ~$98B and 4.6% share, climbing to the fourth-largest category, with ~190 pipeline assets ...

Forbes contributors publish independent expert analyses and insights. Juergen Eckhardt leads Bayer’s impact investment unit, Leaps by Bayer. As a venture investor in healthcare, I am privileged to ...

Stem cell therapy is an emerging treatment for type 2 diabetes. Although it’s not yet FDA-approved in the United States, it is a rapidly expanding and promising field of research. Stem cells are ...

A new algorithm designed to consider all forms of diabetes when diagnosing patients is among the additions in the American ...